Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Search
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
Professor Richeldi treatment initiation
Leading pulmonologist Professor Richeldi discusses why early initiation of treatment in Idiopathic Pulmonary Fibrosis is important.
The UAE MOHAP Approves the First and Only Therapy for the Treatment of Adult Generalized Pustular Psoriasis Flares
The first treatment of its kind in the UAE by Boehringer Ingelheim is the only FDA and EMA-approved medication used to treat GPP flares in adult patients and works to help block a source of inflammation that may cause GPP flares
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
The Bigger Picture of Treatment Sequencing
The Bigger Picture of Treatment Sequencing
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
Interview: Excellence in stem cell treatments
Acquisition of GST reflects the potential of biotechnology research. Goal is to provide breakthrough therapies for diseases in companion animals.
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Research in Diabetic Macular Ischemia
There are no available treatments for DMI. Scientists at Boehringer Ingelheim are working hard to change this.
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Lameness – a common problem in horses
The causes of lameness, and why there is a clear need for innovation and new treatment options.
New approaches in the battle against heartworm disease
Heartworm disease is a concern to dog and cat owners worldwide. Current disease control methods are increasingly challenged by drug resistance. We explore the potential for novel treatments and vaccines based on new knowledge and technology.
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
The ILD summit discussed the latest treatment guidelines for ILD which vastly impacts quality of life
equine asthma
Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
PCI with stenting animation
A short animation explaining what Percutaneous Coronary Intervention (PCI) with stenting is, why it is used in AF patients and the unmet need in current treatment strategies
Retinal health
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
IPF why wait?
IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
First hospital uae and gcc receive international award stroke management
Ibrahim Bin Hamad Obaidullah Hospital Receives the Diamond Award from the World Stroke Organization
Stem cells a new frontier
Stem cells may be a game changer for the development of new veterinary treatments. Read this story to find out why.
Finding the right inhaler for you
Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases